Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

242
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
242
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

338
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
338
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

494
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
494
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

249
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
249
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.9K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.9K
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

526
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
526

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing ethanol-driven chain elongation via iron speciation: impacts on metabolic flux and dual FAB/RBO pathway activation.

Bioresource technology·2026
Same author

De-risking Biopharma Asset Acquisition: Towards a Quantitative Framework for Strategic Decision-making.

The AAPS journal·2026
Same author

Exposure-Response Relationships for Axatilimab in Patients with Chronic Graft-Versus-Host Disease.

Clinical pharmacology and therapeutics·2025
Same author

Effect of Itraconazole or Rifampin on Zilurgisertib Pharmacokinetics When Administered Orally in Healthy Participants.

Clinical pharmacology in drug development·2025
Same author

Leveraging large language models to compare perspectives on integrating QSP and AI/ML.

Journal of pharmacokinetics and pharmacodynamics·2025
Same author

Model-Informed Immunogenicity Assessment of Nivolumab as Monotherapy and in Combination with Ipilimumab.

The AAPS journal·2025
Same journal

Optimizing Subcutaneous Antibody Dosing Regimens Through Operating Space Maps: rHuPH20 Case Study.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Mechanistic modeling of FcRn-dependent IgG drug interactions: Clinical applications and dosing implications.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Comparing heavy-tailed residual error models for outlier handling in population PK modeling.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Personalized prophylactic therapy optimization in hemophilia A using a hybrid PK-PD-TTE model and deep RL.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Pediatric oral cavity physiologically based pharmacokinetic model to predict pharmacokinetics of mucoadhesive atropine gel to treat sialorrhea.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial.

Journal of pharmacokinetics and pharmacodynamics·2026
See all related articles

Related Experiment Video

Updated: Jan 17, 2026

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K

Advancing drug development with "Fit-for-Purpose" modeling informed approaches.

Jennifer Sheng1, Tongli Zhang2

  • 1College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA.

Journal of Pharmacokinetics and Pharmacodynamics
|September 15, 2025
PubMed
Summary
This summary is machine-generated.

Model-informed Drug Development (MIDD) provides a strategic blueprint aligning tools with drug development questions. This framework enhances target identification, clinical trial design, and lifecycle management, integrating emerging technologies like AI.

More Related Videos

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

21.2K
Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

1.1K

Related Experiment Videos

Last Updated: Jan 17, 2026

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

21.2K
Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

1.1K

Area of Science:

  • Pharmacometrics and Drug Development
  • Computational Biology and Bioinformatics

Background:

  • Model-informed Drug Development (MIDD) is crucial for drug development and regulatory decision-making.
  • Existing MIDD strategies require strategic alignment with key questions of interest (QOI) and content of use (COU) across all development stages.

Purpose of the Study:

  • To present a strategic blueprint for aligning MIDD tools with QOI, COU, and model impact throughout the drug development lifecycle.
  • To illustrate MIDD applications in target identification, lead optimization, preclinical accuracy, First-in-Human (FIH) studies, clinical trial design, and post-market support.

Main Methods:

  • Review and synthesis of current MIDD practices and tools.
  • Highlighting common modeling methodologies: QSAR, PBPK, PK/PD, PPK/ER, and QSP.
  • Exploration of MIDD integration with emerging technologies (AI, ML) and its utility in regulatory evaluations (e.g., 505(b)(2) and generic drugs).

Main Results:

  • Demonstrated application of MIDD across various development phases, from early discovery to post-approval label updates.
  • Showcased the role of MIDD in optimizing clinical trial design, dosage, and understanding population pharmacokinetics/exposure-response (PPK/ER).
  • Discussed MIDD's role in regulatory interactions, asset acquisitions, and its evolving integration with AI/ML.

Conclusions:

  • The strategic blueprint effectively aligns MIDD tools with development needs, enhancing efficiency and regulatory support.
  • MIDD is adaptable to emerging technologies and diverse regulatory pathways, offering significant potential for drug development.
  • Addressing challenges like resource allocation and organizational alignment is key to further expanding MIDD's impact.